Dyne Therapeutics to Present New Preclinical Data at ASGCT Annual Meeting…
<!-- Name:DistributionId Value:8830457 -->
<!-- Name:EnableQuoteCarouselOnPnr Value:False -->…
Browsing Tag
Dyne Therapeutics
Dyne Therapeutics Announces Presentations on its DM1 and DMD Programs at the 2023…
<!-- Name:DistributionId Value:8791047 -->
<!-- Name:EnableQuoteCarouselOnPnr Value:False -->…
Dyne Therapeutics Presents Preclinical Data from its Duchenne Muscular Dystrophy…
- Poster Highlights In Vivo Data for DYNE-251, Now Being Evaluated in Phase 1/2 DELIVER Clinical Trial in Patients Amenable to Exon 51 Skipping - - First Presentation of In Vitro Data for…
Dyne Therapeutics to Present at Morgan Stanley 20th Annual Global Healthcare…
WALTHAM, Mass., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming…
Dyne Therapeutics Appoints Francesco Bibbiani, M.D., as Senior Vice President, Head…
- Appointment Expands Dyne’s Development Team as Company Advances Multiple Programs into Clinical Trials - WALTHAM, Mass., Aug. 29, 2022 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc.…
Dyne Therapeutics Announces “Breakthrough Article” Publication of Duchenne Muscular…
- FORCE™ Platform Achieves Enhanced Exon Skipping and Prolonged Dystrophin Restoration in Duchenne in vivo mdx Model - WALTHAM, Mass., Aug. 10, 2022 (GLOBE NEWSWIRE) -- Dyne…
Dyne Therapeutics Announces Clearance of Clinical Trial Application for DYNE-101 for…
- Initiation of Dosing in Multiple Ascending Dose Clinical Trial of DYNE-101 in Patients with DM1 On Track for Mid-2022 - - Executing on Global Clinical and Regulatory Strategy: Clinical…
Dyne Therapeutics Announces FDA Clearance of IND Application for DYNE-251 for the…
- Initiation of Dosing in Multiple Ascending Dose Clinical Trial in Patients with Mutations Amenable to Skipping Exon 51 On Track for Mid-2022 - WALTHAM, Mass., July 05, 2022 (GLOBE…
Dyne Therapeutics Announces Submission of IND Application to Initiate Clinical Trial…
- DYNE-251, Dyne’s First DMD Program, is Being Developed for Patients with Mutations Amenable to Skipping Exon 51 - - DYNE-101 IND Submission in DM1 Expected in the First Quarter of 2022…
Dyne Therapeutics Presents New In Vivo Data for its Duchenne Muscular Dystrophy…
- Dystrophin Restoration of 90% of Wild-Type Levels Observed in the Diaphragm and 78% in the Heart with ~80% Dystrophin-Positive Fibers After a Single Dose in mdx Mouse Model - - DYNE-251…